While Pliant Therapeutics Inc has underperformed by -0.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PLRX fell by -60.79%, with highs and lows ranging from $30.85 to $11.73, whereas the simple moving average fell by -26.03% in the last 200 days.
On December 08, 2023, Wells Fargo started tracking Pliant Therapeutics Inc (NASDAQ: PLRX) recommending Overweight. A report published by Canaccord Genuity on May 18, 2023, Initiated its previous ‘Buy’ rating for PLRX. Robert W. Baird also rated PLRX shares as ‘Outperform’, setting a target price of $44 on the company’s shares in an initiating report dated April 13, 2023. Stifel Initiated an Buy rating on December 14, 2022, and assigned a price target of $33. JP Morgan initiated its ‘Overweight’ rating for PLRX, as published in its report on December 07, 2022. Citigroup’s report from September 01, 2022 suggests a price prediction of $36 for PLRX shares, giving the stock a ‘Buy’ rating. SVB Leerink also rated the stock as ‘Outperform’.
Analysis of Pliant Therapeutics Inc (PLRX)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
Pliant Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -41.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.72, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and PLRX has an average volume of 362.98K. On a monthly basis, the volatility of the stock is set at 4.43%, whereas on a weekly basis, it is put at 4.93%, with a loss of -2.54% over the past seven days. Furthermore, long-term investors anticipate a median target price of $43.00, showing growth from the present price of $11.88, which can serve as yet another indication of whether PLRX is worth investing in or should be passed over.
How Do You Analyze Pliant Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 95.70% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PLRX shares are owned by institutional investors to the tune of 95.70% at present.
